Johnson & Johnson (NYSE:JNJ) VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Johnson & Johnson (JNJ) traded down 0.26% during midday trading on Friday, hitting $133.00. The stock had a trading volume of 1,337,564 shares. The firm has a 50-day moving average of $133.33 and a 200 day moving average of $125.48. The firm has a market capitalization of $358.28 billion, a P/E ratio of 22.50 and a beta of 0.78. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.83%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.74 EPS. On average, equities analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
Several hedge funds have recently added to or reduced their stakes in JNJ. Glenview Trust Co acquired a new position in Johnson & Johnson during the fourth quarter valued at $18,192,000. RBO & Co. LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $24,734,000. Capital Analysts LLC increased its stake in shares of Johnson & Johnson by 6.6% in the fourth quarter. Capital Analysts LLC now owns 24,731 shares of the company’s stock worth $2,849,000 after buying an additional 1,522 shares during the period. CWA Asset Management Group LLC increased its stake in shares of Johnson & Johnson by 13.1% in the fourth quarter. CWA Asset Management Group LLC now owns 55,685 shares of the company’s stock worth $6,415,000 after buying an additional 6,451 shares during the period. Finally, Amtrust Financial Services Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $1,151,000. Institutional investors own 66.01% of the company’s stock.
A number of research firms have issued reports on JNJ. BTIG Research downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price for the company. in a research report on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a report on Friday, July 21st. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Finally, Credit Suisse Group initiated coverage on Johnson & Johnson in a research note on Thursday, July 20th. They set an “outperform” rating and a $148.00 price objective for the company. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $133.72.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
